Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2024 | The clinical significance of a prodromal phase in MS

Helen Tremlett • 9 Oct 2024
ECTRIMS 2024
Multiple Sclerosis and Related Disorders

Helen Tremlett, PhD, The University of British Columbia, Vancouver, Canada, discusses the clinical significance of a prodromal phase in multiple sclerosis (MS). She discusses its importance in understanding the etiology of MS, diagnosing MS earlier, and offering enrolment in neuroprotective clinical trials. This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Helen Tremlett

Lower cognitive performance before MS symptom onset: a Norweigan study
1:57
Lower cognitive performance before MS symptom onset: a Norweigan study
Helen Tremlett • 9 Oct 2024
The concept of an MS prodomal phase and how it has long been neglected
1:29
The concept of an MS prodomal phase and how it has long been neglected
Helen Tremlett • 9 Oct 2024
Increased healthcare use before MS onset as evidence for a potential prodromal phase
3:04
Increased healthcare use before MS onset as evidence for a potential prodromal phase
Helen Tremlett • 9 Oct 2024
Comparing the prodromal phase in MS to other immune-mediated diseases
2:42
Comparing the prodromal phase in MS to other immune-mediated diseases
Helen Tremlett • 9 Oct 2024

Related Videos

Aerobic training and its potential impact on neurogenesis in progressive multiple sclerosis
4:05
Aerobic training and its potential impact on neurogenesis in progressive multiple sclerosis
Tetsu Morozumi • 29 Apr 2026
Emerging treatments for MS: BTK inhibitors, monoclonal antibodies, and CAR T-cells
2:41
Emerging treatments for MS: BTK inhibitors, monoclonal antibodies, and CAR T-cells
Patricia Coyle • 20 Apr 2026
Baseline characteristics to predict response to aerobic training and physical rehabilitation in MS
4:12
Baseline characteristics to predict response to aerobic training and physical rehabilitation in MS
Tetsu Morozumi • 19 Apr 2026
Phase II open-label extension of frexalimab in participants with relapsing multiple sclerosis
6:10
Phase II open-label extension of frexalimab in participants with relapsing multiple sclerosis
Patrick Vermersch • 24 Apr 2026
The content of VJNeurology is intended for healthcare professionals